Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China

Oncotarget

Volumn 7, Issue 3, 2016, Pages 3599-3613

  Song, Bin ^a   Cui, Heyang ^a   Li, Yaoping ^a,b   Cheng, Caixia ^a   Yang, Bin ^a,b   Wang, Fang ^a   Kong, Pengzhou ^a   Li, Hongyi ^a   Zhang, Ling ^a   Jia, Zhiwu ^a   Bi, Yanghui ^a   Wang, Jiaqian ^c   Zhou, Yong ^c   Liu, Jing ^a   Wang, Juan ^a   Zhao, Zhenxiang ^a   Zhang, Yanyan ^a   Hu, Xiaoling ^a   Shi, Ruyi ^a   Yang, Jie ^a   Liu, Haiyan ^a   Yan, Ting ^a   Li, Yike ^a   Xu, Enwei ^a,b   Qian, Yu ^a   Xi, Yanfeng ^b   Guo, Shiping ^b   Chen, Yunqing ^b   Wang, Jinfen ^b   Li, Guodong ^b   Liang, Jianfang ^a   Jia, Junmei ^a   Chen, Xing ^d   Guo, Jiansheng ^a   Wang, Tong ^a   Zhang, Yanbo ^a   Li, Qingshan ^a   Wang, Chuangui ^e   Cheng, Xiaolong ^a   Zhan, Qimin ^f   Cui, Yongping ^a   more..

^a SHANXI MEDICAL UNIVERSITY   (China)

^b SHANXI CANCER HOSPITAL   (China)

^c BGI SHENZHEN   (China)

^d SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^e CHINA MEDICAL UNIVERSITY   (China)

^f CANCER HOSPITAL   (China)

Author keywords

Esophageal cancer; Mutational exclusivity; Oncogene; Significantly mutated genes

Indexed keywords

FLUOROURACIL; NOTCH1 RECEPTOR; PACLITAXEL; ANTINEOPLASTIC AGENT; CISPLATIN; MESSENGER RNA; NOTCH1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER PROGNOSIS; CANCER SURVIVAL; CHINA; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; NOTCH1 GENE; OVERALL SURVIVAL; PIK3CA GENE; APOPTOSIS; CANCER GRADING; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG EFFECTS; ENZYME IMMUNOASSAY; ESOPHAGEAL NEOPLASMS; FOLLOW UP; GENETICS; GENOMICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION; TUMOR RECURRENCE; WESTERN BLOTTING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CHINA; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GENOMICS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, NOTCH1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84962288878     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6120     Document Type: Article

References (36)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent JJemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65:87-108.
2. Pennathur A, Gibson MK, Jobe BALuketich JD. Oesophageal carcinoma. Lancet. 2013; 381:400-412.
3. Sakaeda T, Yamamori M, Kuwahara ANishiguchi K. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Advanced drug delivery reviews. 2009; 61:388-401.
4. Perez-Herrero EFernandez-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2015; 93:52-79.
5. Li XY, Su M, Huang HH, Li H, Tian DPGao YX. mtDNA evidence: genetic background associated with related populations at high risk for esophageal cancer between Chaoshan and Taihang Mountain areas in China. Genomics. 2007; 90:474-481.
6. Wu C, Wang Z, Song X, Feng XS, Abnet CC, He J, Hu N, Zuo XB, Tan W, Zhan Q, Hu Z, He Z, Jia W, et al. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nature genetics. 2014; 46:1001-1006.
7. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, Ma X, Liu L, Zhao Z, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014; 509:91-95.
8. Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, Sato Y, Okuno Y, Varela AM, Ding LW, Garg M, Liu LZ, Yang H, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nature genetics. 2014; 46:467-473.
9. Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun ZM, Zhang F, Zhao ZR, Li ZT, Liu ZY, Zhao YD, Sun J, Zhou CC, et al. Genetic landscape of esophageal squamous cell carcinoma. Nature genetics. 2014; 46:1097-1102.
10. Zhang L, Zhou Y, Cheng C, Cui H, Cheng L, Kong P, Wang J, Li Y, Chen W, Song B, Wang F, Jia Z, Li L, et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. American journal of human genetics. 2015; 96:597-611.
11. Cohen AL, Piccolo SR, Cheng L, Soldi R, Han B, Johnson WEBild AH. Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers. BMC medical genomics. 2013; 6:35.
12. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502:333-339.
13. Kiel MJ, Velusamy T, Rolland D, Sahasrabuddhe AA, Chung F, Bailey NG, Schrader A, Li B, Li JZ, Ozel AB, Betz BL, Miranda RN, Medeiros LJ, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014; 124:1460-1472.
14. Szczurek EBeerenwinkel N. Modeling mutual exclusivity of cancer mutations. PLoS Comput Biol. 2014; 10:e1003503.
15. Dotto GP. Notch tumor suppressor function. Oncogene. 2008 Sep 1;27:5115-5123.
16. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, Hui CC, Clevers H, Dotto GP, Radtke F. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003 Mar;33:416-421.
17. Proweller A, Tu L, Lepore JJ, Cheng L, Lu MM, Seykora J, Millar SE, Pear WS, Parmacek MS. Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res. 2006 Aug 1;66:7438-7444.
18. Stransky N, EgloffAM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26;333:1157-1160.
19. Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, Leigh IM, Collisson EA, Gordon PB, Jakkula L, Pennypacker S, Zou Y, Sharma M, et al. Loss-offunction mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A. 2011 Oct 25;108:17761-17766.
20. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011; 333:1154-1157.
21. Mittal S, Subramanyam D, Dey D, Kumar RVRangarajan A. Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Molecular cancer. 2009; 8:128.
22. Witkowski MT, Cimmino L, Hu Y, Trimarchi T, Tagoh H, McKenzie MD, Best SA, Tuohey L, Willson TA, Nutt SL, Busslinger M, Aifantis I, Smyth GK, et al. Activated Notch counteracts Ikaros tumor suppression in mouse and human T-cell acute lymphoblastic leukemia. Leukemia. 2015; 29:1301-1311.
23. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, Cresta S, Gargiulo E, Forconi F, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. The Journal of experimental medicine. 2011; 208:1389-1401.
24. Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, Liu C, Ibrahim S, Beran M, et al. A novel tumoursuppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011; 473:230-233.
25. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, PfaffE, Tönjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22:425-437.
26. Zheng Y, Cao X, Wen J, Yang H, Luo K, Liu Q, Huang Q, Chen J, Fu J. Smoking affects treatment outcome in patients with resected esophageal squamous cell carcinoma who received chemotherapy. PLoS One 2015;10:e0123246.
27. Pavelic J. Editorial: combined cancer therapy. Curr Pharm Des 2014;20:6511-6512.
28. Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZHe LY. siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells. Asian Pacific journal of cancer prevention: APJCP. 2012; 13:2485-2489.
29. McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH, Daggett J, Jr., Cullen K, KantoffE, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:E2939-2948.
30. Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty PBSchwartz GK. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer research. 2009; 69:573-582.
31. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JNSullenger BA. Notch promotes radioresistance of glioma stem cells. Stem cells. 2010; 28:17-28.
32. Takebe N, Nguyen DYang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacology & therapeutics. 2014; 141:140-149.
33. Shigaki H, Baba Y, Watanabe M, Murata A, Ishimoto T, Iwatsuki M, Iwagami S, Nosho KBaba H. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19:2451-2459.
34. Hou J, Jiang D, Zhang J, Gavine PR, Xu S, Liu Y, Xu C, Huang J, Tan Y, Wang H, Lu Y, Zheng L, Hou Y, et al. Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma. Human pathology. 2014; 45:352-358.
35. Murugan AK, Munirajan AKTsuchida N. Genetic deregulation of the PIK3CA oncogene in oral cancer. Cancer letters. 2013; 338:193-203.
36. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, et al. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 3:1566-75. doi: 10.18632/oncotarget.716.